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3 months. SBAH staff followed up patients who missed their visits by phone, and confirmed vital status (based on national identification number) with the SA Department of Home Affairs as part of routine care.
Participants
We included all adult patients (≥18 years) with clinically or histologically diagnosed KS who accessed oncology care at the SBAH medical oncology unit between May 2004 and September 2012. We excluded HIV-negative patients and those whose HIV status was unknown. Data on eligible KS patients were extracted from the SBAH medical oncology unit's electronic database. We used a data collection form to capture additional information from paper records. We extracted the following data: demographic characteristics, baseline CD4+ count, HIV RNA viral load, haemoglobin concentration, other HIV-related comorbidities, date of KS diagnosis, KS site, AIDS Clinical Trials Group (ACTG) KS stage, [11, 12] HIV status, ART use, date of starting ART, chemotherapy and radiation therapy, date of last visit, and patient outcome. Outcomes were defined as alive and in care at SBAH, referred/transferred to another facility, death, confirmed loss to follow-up (>6 months from missed scheduled visit, but confirmed to be alive through Home Affairs) and unknown outcome (>6 months from missed scheduled visit, but vital status unknown). Patients who were alive and in care at SBAH or referred/ transferred to another facility were classified as retained in care. Data were captured with EpiData software (EpiData version 3.1, EpiData Association, Denmark).
Data analysis
Patient characteristics by ART period were described with frequencies, medians and interquartile ranges (IQRs). Time was measured from date of KS diagnosis to date of death or last clinic visit. We used Kaplan-Meier survival functions to estimate overall survival and survival by ART period at 1 and 2 years' follow-up. We also estimated survival and retention in care at 1 and 2 years' follow-up. We used uni-and multivariable Cox regression models to determine changes over calendar years, defined as early (2004 -2008) v. late (2009 -2012) ART periods. In the multivariable Cox model, we adjusted the effect of ART period for gender, age, baseline CD4+ count, ACTG KS stage, history of tuberculosis (TB) infection, ART status at KS diagnosis, chemotherapy and radiation therapy. We performed multiple imputation, using chained equations to correct for missing ACTG KS stage (26.0% missing), baseline CD4+ count (11.5% missing) and baseline haemoglobin (8.1% missing) in the multivariable model. In sensitivity analyses, we fitted Cox regression models for the composite outcome of mortality and loss to follow-up. All analyses were done using Stata version 13 (Stata Corporation, USA).
Ethics approval
Informed consent was sought from all cancer patients in the SBAH medical oncology unit, requesting the use of their deidentified medical records for research publication. The median follow-up time over the whole study period was 9.6 (IQR 2.2 -23) months.
Results

Characteristics of patients with AIDS-KS and changes over time
Compared with the early ART period (2004 -2008) , patients diagnosed with KS in the late ART period (2009 -2012) had, on average, higher CD4+ cell counts than those diagnosed in the early period (250 v. 233 cells/µL). Patients in the late ART period also had lower HIV RNA viral loads (median 3.2 v. 7.6 log 10 copies/mL), and were more often on ART at KS diagnosis (72.7% v. 53.8%). In the later period, only 2.5% of patients received no ART before or after diagnosis; 12.1% had received no ART in the early period. The proportion of patients who received chemotherapy or radiotherapy did not change over time. Patients diagnosed in the late period were more likely to be male (66.7% v. 57.9%) and more likely to be diagnosed at advanced ACTG KS stages (56.6% v. 42.8%). The proportion of unstaged patients decreased from 31.4% in the early period to 21.7% in the late period.
Survival and retention in care
At end of the study period, 181 patients (50.7%) were alive and in care at SBAH, 95 (26.6%) had died, 39 (10.9%) were lost to followup (>6 months from missed scheduled visit, but confirmed to be alive through Home Affairs), 23 (6.4%) had unknown outcomes (>6 months from missed scheduled visit, but vital status unknown), and 19 (5.3%) were discharged or transferred. Overall survival in all patients at 1 and 2 years' follow-up was 78.5% (95% confidence interval (CI) 72.9 -83.0) and 66.7% (95% CI 59.8 -72.8), respectively. Patients diagnosed in the late ART period had higher survival rates than those diagnosed in the early ART period. One-year survival was 72.0% (95% CI 63.3 -83.0) in the early period and 84.6% (95% CI 77.5 -89.6) in the late period, while 2-year survival was 55.8% (95% CI 45.8 -64.7) in the early period and 79.0% (95% CI 69.9 -85.6) in the late period (Table 2) . Likewise, patients diagnosed in the late ART period had higher survival and retention rates than those diagnosed in the early ART period ( Fig. 1 ). One-year survival and retention was 60.4% (95% CI 51.8 -67.9) in the early period and 72.3% (95% CI 64.3 -78.8) in the late period, while 2-year survival and retention was 39.8% (95% CI 31.3 -48.1) in the early period and 66.7% (95% CI 57.6 -74.2) in the late period ( Table 2 ). Patients who received chemotherapy had higher survival and retention rates than those who did not. One-year survival and retention was 50.5% (95% CI 41.9 -58.4) in the patients who did not receive chemotherapy and 83.2% (95% CI 75.9 -88.4) in the patients who did receive it, while RESEARCH 2-year survival and retention was 36.8% (95% CI 28.1 -45.6) in the patients who did not receive chemotherapy and 66.9% (95% CI 57.5 -74.7) in those who did receive it.
Changes over time and predictors of mortality
In univariable analyses, patients in the late period were more likely to survive than those in the early period (hazard ratio (HR) 0.41, 95% CI 0.26 -0.64) ( Table 3 ). We confirmed this association (HR 0.37, 95% CI 0.19 -0.73) after adjusting for age, gender, baseline CD4+ count, baseline haemoglobin, ACTG KS stage, TB comorbidity, ART use at KS diagnosis, chemotherapy and radiation therapy. In both univariable and multivariable analyses, ACTG poor-risk stage (adjusted HR 2.88, 95% CI 1.36 -6.09) was associated with increased mortality. A previous history of TB was associated with mortality in univariable (HR 1.64, 95% CI 1.05 -2.57) but not in multivariable analyses. Receiving chemotherapy was associated with better survival in both univariable and multivariable analyses (adjusted HR 0.30, 95% CI 0.15 -0.61). After correction for missing data, radiation RESEARCH therapy (HR 0.52, 95% CI 0.33 -0.81) was also associated with better survival in the multivariable analyses. HRs from the imputed model were similar to those from complete case analyses. In sensitivity analyses, predictors of the composite outcome of mortality and loss to follow-up were similar to predictors of mortality (Table 4 ).
Discussion
We found that survival of KS patients at the SBAH medical oncology unit has substantially improved in recent years. We were the first to demonstrate that KS survival increased significantly after the advent of ART in an African setting. We found good survival rates of KS patients in routine care, treated with ART and chemotherapy (ABV or oral VP16) and/or radiotherapy for selected patients. The overall 1-year survival rate of 78.5% is comparable to survival estimates from other SA studies, [8, 9, 13] including a clinical trial that used similar chemotherapy regimens. [9] An observational study in the USA estimated 2-year survival rates 
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comparable to what we found in the late ART period in SA (81% and 79%, respectively). [14] This suggests that ART in HIV-positive KS patients combined with standard-of-care chemotherapy regimens and/or radiotherapy in selected patients yields favourable survival outcomes and is a practical option in high-burden resource-limited settings. We confirmed the findings of other studies that advanced KS stage [10, 11, 15, 16] predicts mortality, while chemotherapy [8, 17] increases the chance of survival in KS patients. Unlike other SA studies, [13, 18] we found no gender differences in mortality. Our study showed that both chemotherapy and radiation therapy were associated with improved survival. We suggest that referral for oncology care be considered for KS patients with failure of regression of lesions on ART alone, and for those with advanced disease. Recording of KS surveillance data at lower-level clinics will allow estimation of prognosis of KS across different stages. Our findings reflect the success of the national ART programme, but also underline the need to reduce KS-associated morbidity and mortality further through early ART initiation. During the study period (2004 -2012) the ART eligibility criteria were a CD4+ count <200/µL or a World Health Organization stage IV AIDS-defining condition. [19] Adult ART coverage rose from 5.1% in 2004 to 79% in 2011, [6, 7] and this improved ART coverage is reflected in the improved ART status of patients in the later ART period in our study. In spite of improved ART coverage, KS incidence in HIV-positive southern Africans remains unacceptably high, even in patients on ART, [20] because only patients with significant immune impairment were eligible for ART. This underscores the need and potential impact of the test-and-treat strategy that SA adopted from September 2016. [21] 
Study strengths and limitations
Our study had several strengths and some weaknesses. The SBAH medical oncology unit has good paper and electronic record systems, traces defaulters by phone, and routinely confirms vital status with the SA Department of Home Affairs. This allowed us to ascertain deaths and document date of death, so that vital status was unknown in only 23 patients (6.4%). KS was pathologically confirmed in nearly all patients (n=355, 99.4%). Most KS patients had a documented HIV result (370/374), so we could include 95% of all KS patients in the analyses. The retrospective nature of our study did result in missing data, but we corrected for this with multiple imputation and confirmed the findings from the complete case analyses ( Table 3 ). The KS patients in our study were mostly black Africans between 20 and 50 years of age, which reflects national HIV prevalence distribution, where this key population has the highest HIV seroprevalence. [5, 22] There was potential for selection bias in our study. We conducted our study at a tertiary academic hospital that may provide better care than most other healthcare facility levels. There was potential for selecting patients who had survived long enough to go through the referral RESEARCH system, those who had better healthcare access and also those who were sick enough to warrant referral to a tertiary hospital. [23] We had a total of 374 KS patients over the 8-year study period, which is a very small number given the high incidence of KS in HIV-positive people in SA. It is likely that many patients with early-stage KS were never referred for oncology care and were treated with ART only at their local HIV clinics. Furthermore, SA is a middle-income country and access to cancer care may be better than in other African settings, [24] making these findings less generalisable to other African settings.
Conclusions
Large national ART programmes like the one in SA can successfully reduce KS-related mortality at the individual patient level. If ART coverage is extended, KS-associated morbidity and mortality are likely to drop.
